Clinical Trials
Clinical Trial Detail
Return to search results.
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Complete title: A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors
| Research Study Number | 20120892 | ||
| Principal Investigator | Laura Chow | ||
| Phase | I |
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Genders Eligible for Study: Both
- All subjects will have locally advanced or metastatic cancer resistant to standard treatment, for which no additional standard treatment is available, or for which the subject declines standard treatment, excluding cancer in the blood; in Part 2 (Cohort Expansion), tumor types will be further restricted to clear cell renal cell carcinoma or non-small cell lung cancer
- At least 1 non-irradiated lesion with measurable disease at baseline
- Availability of an existing tumor biopsy sample (or consent to allow pre-treatment tumor biopsy if sample not available)
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
- Certain prior drug treatments for the cancer
- Autoimmune disease
- Inadequate liver or kidney function
Other exclusion criteria may apply.
|
Keywords
Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
- Diseases
& Research
- Treatment
& Support
- About Us
- Labs &
Projects
- Events &
Community Programs
- How You
Can Help Us
The Hutchinson Center's world-renowned scientists are discovering new ways to detect, prevent and treat cancer, HIV/AIDS and many other diseases.
- License Our Discoveries
The Hutchinson Center's world-renowned researchers work together to pursue lifesaving therapies that will help eliminate cancer and related diseases.
The Hutchinson Center's clinical research breakthroughs are delivered to patients through our treatment arm, the Seattle Cancer Care Alliance. This collaboration combines the strengths of the Hutchinson Center, UW Medicine and Seattle Children's.
You can help eliminate cancer and related diseases by attending Hutchinson Center events and participating in our other fundraising and community efforts.
- Divisions
The Hutchinson Center's pioneering researchers push the boundaries of science to find new ways to prevent, detect and treat cancer and related diseases.
Private support is critical to fund new research ideas and innovations, accelerating our ability to make lifesaving discoveries.
